Arcellx, Inc. - Common Stock (OQ:ACLX)
Business Focus: N/A
Apr 04, 2024 04:00 pm ET
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET.
Mar 20, 2024 04:00 pm ET
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET.
Dec 08, 2023 03:00 pm ET
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months –
Nov 15, 2023 06:00 am ET
Kite and Arcellx Announce Expansion in Strategic Partnership
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced i
Nov 15, 2023 05:00 am ET
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment --
Nov 13, 2023 03:00 pm ET
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
-- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median follow-up of 22 months after CART-ddBCMA infusion --
Nov 02, 2023 09:00 am ET
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
-- Abstract released today is from a June 2, 2023 data cut --
Oct 26, 2023 04:00 pm ET
Arcellx to Participate in Two Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the management team will participate in two upcoming investor conferences:
Jul 19, 2023 02:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. (“Arcellx” or the “Company”) (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 17, 2023 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK, July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 12, 2023 01:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK, July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 09, 2023 02:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. (“Arcellx” or the “Company”) (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 03, 2023 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK, July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 01, 2023 11:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. (“Arcellx” or the “Company”) (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 25, 2023 08:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. (“Arcellx” or the “Company”) (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 23, 2023 11:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK, June 23, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 20, 2023 09:31 am ET
Thinking about trading options or stock in Dice Therapeutics, Arcellx, Coherent, US Foods Holding, or Microsoft?
NEW YORK, June 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DICE, ACLX, COHR, USFD, and MSFT.
Jun 19, 2023 07:46 pm ET
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion --
May 23, 2023 11:29 am ET
Thinking about buying stock in Lucid, Immunovant, Arcellx, Vista Energy, or Terns Pharmaceuticals?
NEW YORK, May 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, IMVT, ACLX, VIST, and TERN.
May 08, 2023 04:00 pm ET
Arcellx Provides First Quarter Financial Results
REDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023.
Apr 13, 2023 04:01 pm ET
Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif., April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 1:00 p.m. ET.
Mar 29, 2023 04:01 pm ET
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma --
Feb 02, 2023 03:00 pm ET
Arcellx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the company's participation in the following investor conferences:
Jan 30, 2023 09:00 am ET
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop
Dec 09, 2022 08:17 am ET
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
Dec 09, 2022 07:17 am ET
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress
-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors --
Dec 09, 2022 07:15 am ET
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing --
Nov 14, 2022 03:00 pm ET
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
-- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA --
Nov 03, 2022 09:00 am ET
Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition
-- ASH abstract contains previously presented data from June 2022 --
Sep 07, 2022 04:01 pm ET
Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 7, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 3:30 p.m. ET.
Aug 15, 2022 04:00 pm ET
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results
-- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares --
Jun 21, 2022 04:05 pm ET
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.
Jun 21, 2022 04:01 pm ET
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds raised in the offering were $128.8 million, before deducti
Jun 15, 2022 10:47 pm ET
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering
-- Public Offering of 7,000,000 Shares of Common Stock for Gross Proceeds of $112 Million --
Jun 03, 2022 04:00 pm ET
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting
-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors --
May 23, 2022 04:05 pm ET
Arcellx Appoints Michelle Gilson as Chief Financial Officer
FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.
May 16, 2022 04:01 pm ET
Arcellx Appoints Olivia Ware to Board of Directors
-- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors --
May 12, 2022 04:01 pm ET
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) --
May 10, 2022 04:01 pm ET
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients wit
-- ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and overcome tumor heterogeneity --
May 09, 2022 04:01 pm ET
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
100% ORR; 75% CR/sCR; and evidence of durable clinical benefit in a population with poor prognostic features observed in the dose escalation cohorts with CART-ddBCMA
May 05, 2022 04:01 pm ET
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference
FOSTER CITY, Calif., May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:00 p.m. E.T.
Apr 27, 2022 10:00 am ET
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical On
-- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, June 5, 2022, at 7:00 PM CDT --
Apr 08, 2022 01:00 pm ET
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research A
-- ACLX-002 completely regresses multiple cell line and patient-derived AML xenografts --
Mar 24, 2022 04:01 pm ET
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
-- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purchase additional shares --
Mar 10, 2022 03:26 pm ET
Arcellx Announces Participation at the Barclays Global Healthcare Conference
FOSTER CITY, Calif., March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chief executive officer, Rami Elghandour and chief medical officer, Chris Heery, M.D.,will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022, at 4:50 p.m. E.T.
Mar 08, 2022 04:25 pm ET
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Can
FOSTER CITY, Calif., March 8, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the upcoming presentation at the American Association for Cancer Research Annual Meeting 2022 of pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myeloid Leukemia (AML). ACLX-002 can be activated in a dose dependent manner in vivo with soluble protein adapters allowing for c
Feb 08, 2022 04:01 pm ET
Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its initial public offering...
Feb 04, 2022 01:56 am ET
Arcellx Announces Pricing of Initial Public Offering
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.